Syntara's (ASX:SNT) final phase 2 results for its myelofibrosis drug candidate SNT-5505 have shown that the drug was safe and well-tolerated, according to a Tuesday note from Euroz Hartleys.
According to the note, the drug candidate has shown symptom improvement as well as spleen volume reduction in the trial.
The research firm also noted that the company has appointed several global experts to a new strategic and clinical advisory board, including Adam Craig, former chief executive of BioPharma.
Euroz Hartleys has maintained its speculative buy rating on Syntara with a price target of AU$0.22.
The company's shares rose almost 19% in recent Tuesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.